Investment summary

4SC remains focused on finding an ex-Japan partner for resminostat, the oral pan-HDAC inhibitor that could – funding permitting – enter a Phase III trial in hepatocellular carcinoma next year. Another partnering opportunity is vidofludimus, now focused on inflammatory bowel disease rather than rheumatoid arthritis. 4SC ended the first quarter with cash of €12m, and with a projected monthly burn of €1.2m this will last until early 2013 in the absence of licensing deals or other forms of fund-raising.

Last updated on 14/05/2012

Industry outlook

In 2013 4SC is due to report results of a second Phase I/II resminostat trial (SHORE), in second-line metastatic colorectal cancer, and licensing activity on vidofludimus is another possible near-term catalyst. Cash reach has been extended thanks to a near-term focus only on vidofludimus, resminostat and 4SC-202.

Last updated on 23/04/2012